Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-03-24
2009-10-13
Badio, Barbara P (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S172000, C514S182000, C540S107000, C540S112000, C540S113000, C540S114000, C552S548000, C552S550000, C552S551000
Reexamination Certificate
active
07601706
ABSTRACT:
This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
REFERENCES:
patent: 3326758 (1967-06-01), Irmscher et al.
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4560512 (1985-12-01), Firestone
patent: 4866044 (1989-09-01), Sato et al.
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5541348 (1996-07-01), Arya et al.
patent: 5563175 (1996-10-01), Silverman et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 5695738 (1997-12-01), Anderson et al.
patent: 5725840 (1998-03-01), Klaveness et al.
patent: 6020370 (2000-02-01), Horwell et al.
patent: 6028214 (2000-02-01), Silverman et al.
patent: 6103932 (2000-08-01), Horwell et al.
patent: 6117906 (2000-09-01), Silverman et al.
patent: 6143738 (2000-11-01), Zasloff
patent: 6900192 (2005-05-01), Cundy et al.
patent: 6984634 (2006-01-01), Cundy et al.
patent: 6992076 (2006-01-01), Gallop et al.
patent: 7049305 (2006-05-01), Cundy et al.
patent: 7053076 (2006-05-01), Bhat et al.
patent: 7144877 (2006-12-01), Gallop et al.
patent: 2005/0272710 (2005-12-01), Gallop et al.
patent: 2005/0288228 (2005-12-01), Cundy et al.
patent: 2006/0030551 (2006-02-01), Bhat et al.
patent: 2006/0166858 (2006-07-01), Cundy et al.
patent: 2007/0015716 (2007-01-01), Gallop et al.
patent: 0 272 462 (1992-06-01), None
patent: 11-60594 (1999-03-01), None
patent: WO 92/09560 (1992-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/08671 (1999-02-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 99/31057 (1999-06-01), None
patent: WO 99/31074 (1999-06-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/61424 (1999-12-01), None
patent: WO 00/15611 (2000-03-01), None
patent: WO 00/23067 (2000-04-01), None
patent: WO 00/31020 (2000-06-01), None
patent: WO 00/50027 (2000-08-01), None
patent: WO 01/20331 (2001-03-01), None
Adibi, The Oligopeptide transporter (Pept-1) in human intestine: Biology and Function.Gastroenterology1997, 113, 332-40.
Ballatore et al., Synthesis and spectroscopic analysis of bile salts.Steroids1983, 41(2), 197-206.
Baringhaus et al, Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na+/ bile acid cotransporter.J. Lipid Res. 1999, 40, 2158-68.
Batta et al., Characterization of sarcosylsarcoursodeoxycholic acid formed during synthesis of sarcoursodeoxycholic acid.J Lipid Res1989, 30(5), 771-774.
Bryans et al., 3-Substituted GABA analogs with central nervous system activity: a review.Med. Res. Rev. 1999, 19,149-77.
Bundgaard,Design of Prodrugs(Bundgaard, H. Ed.),Elsevier Science B.V., 1985, pp. 1-92.
Dieck et al., The peptide transporter pepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative β-Ala-Lys-Nε-AMCA in Astrocytes.GLIA1999, 25, 10-20.
Ho, Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption.Ann. N. Y. Acad. Sci. 1987, 507, 315-29.
Huijjhebaert et al., Pancreatic carboxypeptidase hydrolysis of bile acid-amino acid conjugates: selective resistance of glycine and taurine amidates.Gastroenterology1986, 90(2), 306-15.
Jezyk et al., Transport of pregabalin in rat intestine and Caco-2 monolayers.Pharm. Res. 1999, 16, 519-26.
Kagedahl et al., Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity.Pharm. Res. 1997, 14, 176-80.
Kim et al., Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides.J. Drug Targeting1993, 1, 347-59.
Kramer et al., Bile acid derived HMG-CoA reductase inhibitors.Biochim. Biophys. Acta. 1994b, 1227, 137-54.
Kramer et al., Intestinal absorption of peptides by coupling to bile acids.J. Biol. Chem. 1994a, 269, 10621-27.
Kramer et al., Liver-specific drug targeting by coupling to bile acids.J. Biol. Chem. 1992, 267, 18598-604.
Kramer et al., Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters.J. Lipid Res. 1999, 40, 1604-17.
Kullak-Ublick et al., Hepatobiliary transport.J. Hepatology2000, 32 (Suppl. 1), 3-18.
Leibach et al., Peptide transporters in the intestine and the kidney.Ann. Rev. Nutr. 1996, 16, 99-119.
Mills et al., Ileal absorption of tyrosine-conjugated bile acids in Wistar rats.Biochim. Biophys. Acta1987, 926, 154-59.
Nair et al., Electron impact ionization mass spectra of lithocholyl amides: evidences fro a C(20) to C(23) rearrangement involving the loss of a C4H9fragment.Organic Mass Spectrometry1994, 29(7), 335-41.
Navia et al., Design principles for orally bioavailable drugs.Drug Discovery Today1996, 1, 179-89.
Petzinger et al., Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids.Hepatology1995, 22, 1801-11.
Russell-Jones et al., Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin.Bioconjugate Chemistry1995, 6, 459-465.
Shah et al., Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells.J Pharmaceutical Sciences1996, 85(12), 1306-1311.
Swaan et al., Enhanced transepithelial transport of peptides by conjugation to cholic acid.Bioconj. Chem.1997, 8, 520-25.
Swaan et al., Preface.Advanced Drug Delivery Reviews. 1996, 20, p. 1-3.
Swaan et al., Use of the intestinal and hepatic bile acid transporters for drug delivery.Adv. Drug Delivery Rev. 1996, 20, 59-82.
Tsuji et al., Carrier-mediated intestinal transport of drugs.Pharm. Res.1996, 13, 963-77.
Wang et al., Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain.Am. J. Physiol. 1998, 275, C967-C975.
International Preliminary Report on Patentability issued May 16, 2006 in International Application No. PCT/US02/27458.
International Search Report issued Feb. 26, 2003 in International Application No. PCT/US02/27458.
International Preliminary Report on Patentability issued Oct. 16, 2003 in International Application No. PCT/US01/42612.
International Search report issued Mar. 26, 2003 in International Application No. PCT/US01/42612.
International Preliminary Report on Patentability issued Apr. 16, 2005 in International Application No. PCT/US01/31486.
International Search report issued Jan. 23, 2002 in International Application No. PCT/US01/31486.
International Preliminary Report on Patentability issued Aug. 4, 2003 in International Application No. PCT/US01/42613.
International Preliminary Report on Patentability issued May 7, 2003 in International Application No. PCT/US01/42513.
International Search report issued Jan. 22, 2002 in International Application No. PCT/US01/42513.
Cundy Kenneth C.
Gallop Mark A.
Zhou Cindy X.
Badio Barbara P
Chang Lucy S.
Lambert William R.
Miller D. Byron
XenoPort, Inc.
LandOfFree
Bile-acid conjugates providing for sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid conjugates providing for sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid conjugates providing for sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142553